Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFα and IL-1β

Cytokine

Volumn 49, Issue 2, 2010, Pages 171-176

  Hong, Jaewoo ^a   Bae, Suyoung ^a   Kang, Youngsun ^a   Yoon, Doyoung ^b   Bai, Xiyuan ^c   Chan, Edward D ^c   Azam, Tania ^d   Dinarello, Charles A ^d   Lee, Siyoung ^a   Her, Erk ^a   Rho, Gyujin ^e   Kim, Soohyun ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Konkuk University   (South Korea)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e Gyeongsang National University   (South Korea)

Author keywords

Arthritis rheumatoidarthritis; Cytokines; Endotoxin LPS; Inflammation; Macrophages monocytes

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL;

ANIMALS; CELL LINE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKINS; MACROPHAGES; MONOCYTES; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73849136741     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.10.003     Document Type: Article

References (31)

1. Kim S.H., Han S.Y., Azam T., Yoon D.Y., and Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22 (2005) 131-142
2. Netea M.G., Azam T., Lewis E.C., Joosten L.A., Wang M., Langenberg D., et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 3 (2006) e277
3. Bombardieri M., McInnes I.B., and Pitzalis C. Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Ther 7 (2007) 31-40
4. Dinarello C.A., and Kim S.H. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65 Suppl. 3 (2006) iii61-iii64
5. McInnes I.B., Liew F.Y., and Gracie J.A. Interleukin-18: a therapeutic target in rheumatoid arthritis?. Arthritis Res Ther 7 (2005) 38-41
6. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Walsh M., Park J.S., et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 102 (2005) 16309-16314
7. Netea M.G., Lewis E.C., Azam T., Joosten L.A., Jaekal J., Bae S.Y., et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA 105 (2008) 3515-3520
8. Novick D., Rubinstein M., Azam T., Rabinkov A., Dinarello C.A., and Kim S.H. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 103 (2006) 3316-3321
9. Frosch M., and Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr 163 (2004) 425-434
10. Lamprecht P., and Gross W.L. Wegener's granulomatosis. Herz 29 (2004) 47-56
11. Sugawara S. Immune functions of proteinase 3. Crit Rev Immunol 25 (2005) 343-360
12. Joosten L.A., Netea M.G., Kim S.H., Yoon D.Y., Oppers-Walgreen B., Radstake T.R., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103 (2006) 3298-3303
13. Mun S.H., Kim J.W., Nah S.S., Ko N.Y., Lee J.H., Kim J.D., et al. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum 60 (2009) 678-685
14. Shoda H., Fujio K., Yamaguchi Y., Okamoto A., Sawada T., Kochi Y., et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 8 (2006) R166
15. Beutler B., and Bazzoni F. TNF, apoptosis and autoimmunity: a common thread?. Blood Cells Mol Dis 24 (1998) 216-230
16. Kumar S., Hanning C.R., Brigham-Burke M.R., Rieman D.J., Lehr R., Khandekar S., et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 18 (2002) 61-71
17. Meazza R., Verdiani S., Biassoni R., Coppolecchia M., Gaggero A., Orengo A.M., et al. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 12 (1996) 2187-2192
18. Nishimura H., Washizu J., Nakamura N., Enomoto A., and Yoshikai Y. Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA. J Immunol 160 (1998) 936-942
19. Pufe T., Petersen W., Tillmann B., and Mentlein R. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum 44 (2001) 1082-1088
20. Goda C., Kanaji T., Kanaji S., Tanaka G., Arima K., Ohno S., et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 18 (2006) 233-240
21. Choi J.D., Bae S.Y., Hong J.W., Azam T., Dinarello C.A., Her E., et al. Identification of the most active interleukin-32 isoform. Immunology 126 (2009) 535-542
22. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
23. Tabara H., Grishok A., and Mello C.C. RNAi in C. elegans: soaking in the genome sequence. Science 282 (1998) 430-431
24. Nicklin M.J., Hughes D.E., Barton J.L., Ure J.M., and Duff G.W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 191 (2000) 303-312
25. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50 (2004) 277-290
26. Darlington C. PEG-sTNF-RI. Amgen. Curr Opin Invest Drugs 4 (2003) 583-587
27. Geletka R.C., and St. Clair E.W. Infliximab for the treatment of early rheumatoid arthritis. Expert Opin Biol Ther 5 (2005) 405-417
28. Nahar I.K., Shojania K., Marra C.A., Alamgir A.H., and Anis A.H. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 37 (2003) 1256-1265
29. Boehncke W.H., Prinz J., and Gottlieb A.B. Biologic therapies for psoriasis. A systematic review. J Rheumatol 33 (2006) 1447-1451
30. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 201 (2005) 1355-1359
31. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 (2006) 704-712